Overcoming mutation-based resistance to antiandrogens with rational drug design

Minna D. Balbas, Michael J. Evans, David J. Hosfield, John Wongvipat, Vivek K. Arora, Philip A. Watson, Yu Chen, Geoffrey L. Greene, Yang Shen, Charles L. Sawyers

Research output: Contribution to journalArticlepeer-review

312 Scopus citations


The second-generation antiandrogen enzalutamide was recently approved for patients with castration-resistant prostate cancer. Despite its success, the duration of response is often limited. For previous antiandrogens, one mechanism of resistance is mutation of the androgen receptor (AR). To prospectively identify AR mutations that might confer resistance to enzalutamide, we performed a reporter-based mutagenesis screen and identified a novel mutation, F876L, which converted enzalutamide into an AR agonist. Ectopic expression of AR F876L rescued the growth inhibition of enzalutamide treatment. Molecular dynamics simulations performed on antiandrogen-AR complexes suggested a mechanism by which the F876L substitution alleviates antagonism through repositioning of the coactivator recruiting helix 12. This model then provided the rationale for a focused chemical screen which, based on existing antiandrogen scaffolds, identified three novel compounds that effectively antagonized AR F876L (and AR WT) to suppress the growth of prostate cancer cells resistant to enzalutamide.

Original languageEnglish
Article numbere00499
Issue number2
StatePublished - Apr 9 2013


Dive into the research topics of 'Overcoming mutation-based resistance to antiandrogens with rational drug design'. Together they form a unique fingerprint.

Cite this